Handle high call volumes more efficiently and quickly.
Today, about 90% of insurance companies do not have the ability to adjudicate the COVID-19 claims.
Therefore, when a patient arrives for a COVID-19 test or treatment, about 90% of their claims are denied, and the patient is forced to pay for any blood test upfront—usually around $2,000.
This problem ends up hitting insurance companies’ contact centers which are dealing with a high volume of calls.
A publicly funded healthcare system in Europe is building an audit robot to survey claims data. This should help people to get a more immediate and clear view of their eligibility to access insurance money for their blood test.